Around half the patients had type 2 diabetes, and none had type 1 diabetes [106]
Lot-specific identifiers, assay values, and methods are maintained in that record and are not repeated in this product dossier
What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
406 Additionally, the study hinted at nephroprotective properties of topiroxostat compared to allopurinol
Im oversimplifying, you know, in that space
Aside from regulating blood glucose levels, GLP-1, the intestinal hormone, also has anti-inflammatory, anti-apoptotic, and antioxidative effects